A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lytle Nikki K, Ferguson L Paige, Rajbhandari Nirakar, Gilroy Kathryn, Fox Raymond G, Deshpande Anagha, Schürch Christian M, Hamilton Michael, Robertson Neil, Lin Wei, Noel Pawan, Wartenberg Martin, Zlobec Inti, Eichmann Micha, Galván José A, Karamitopoulou Eva, Gilderman Tami, Esparza Lourdes Adriana, Shima Yutaka, Spahn Philipp, French Randall, Lewis Nathan E, Fisch Kathleen M, Sasik Roman, Rosenthal Sara Brin, Kritzik Marcie, Von Hoff Daniel, Han Haiyong, Ideker Trey, Deshpande Aniruddha J, Lowy Andrew M, Adams Peter D, Reya Tannishtha
Аннотация
Drug resistance and relapse remain key challenges in pancreatic cancer. Here, we have used RNA sequencing (RNA-seq), chromatin immunoprecipitation (ChIP)-seq, and genome-wide CRISPR analysis to map the molecular dependencies of pancreatic cancer stem cells, highly therapy-resistant cells that preferentially drive tumorigenesis and progression. This integrated genomic approach revealed an unexpected utilization of immuno-regulatory signals by pancreatic cancer epithelial cells. In particular, the nuclear hormone receptor retinoic-acid-receptor-related orphan receptor gamma (RORγ), known to drive inflammation and T cell differentiation, was upregulated during pancreatic cancer progression, and its genetic or pharmacologic inhibition led to a striking defect in pancreatic cancer growth and a marked improvement in survival. Further, a large-scale retrospective analysis in patients revealed that RORγ expression may predict pancreatic cancer aggressiveness, as it positively correlated with advanced disease and metastasis. Collectively, these data identify an orthogonal co-option of immuno-regulatory signals by pancreatic cancer stem cells, suggesting that autoimmune drugs should be evaluated as novel treatment strategies for pancreatic cancer patients.